National Board Dental Examination / Integrated National Board Dental Examination (INBDE) Pharmacology and Pain/Anxiety Management Syllabus

Pharmacology and Pain/Anxiety Management syllabus — full chapter and topic list

Expand any chapter to see its topics and sub-topics. This is the whole examinable outline for Pharmacology and Pain/Anxiety Management in National Board Dental Examination / Integrated National Board Dental Examination (INBDE), not a summary of it.

1. 1

   Pharmacologic Principles

   4 topics

   • Pharmacokinetics: absorption, distribution, metabolism, excretion
   • Pharmacodynamics and dose-response relationships
     • Agonists, antagonists, and receptor theory
     • Therapeutic index and toxicity
   • Drug interactions and adverse reactions
   • Autonomic nervous system pharmacology
2. 2

   Local Anesthetics and Pain Control

   3 topics

   • Mechanism of action and chemistry of local anesthetics
     • Amides versus esters
     • Vasoconstrictor rationale and limits
   • Maximum recommended doses and toxicity management
   • Analgesics: NSAIDs, acetaminophen, and opioids
     • Multimodal analgesia for dental pain
     • Opioid stewardship and prescribing safety
3. 3

   Antimicrobials and Therapeutic Agents

   4 topics

   • Antibiotics in dentistry and resistance
     • Spectrum and indications for common agents
     • Antibiotic prophylaxis guidelines
   • Antifungal and antiviral agents for oral disease
   • Anti-inflammatory and corticosteroid therapy
   • Hemostatic and fluoride therapeutic agents
4. 4

   Sedation and Systemic Drug Considerations

   3 topics

   • Anxiolytics and minimal/moderate sedation pharmacology
     • Nitrous oxide-oxygen sedation
     • Benzodiazepines and monitoring
   • Cardiovascular and anticoagulant medications
   • Endocrine, psychiatric, and respiratory medication impacts on care

Pharmacology and Pain/Anxiety Management flashcards for National Board Dental Examination / Integrated National Board Dental Examination (INBDE)

19 of 50 cards from the Pharmacology and Pain/Anxiety Management deck — real questions with worked answers.

1. What are the four core pharmacokinetic processes that describe a drug's movement through the body (ADME)?

   Absorption (entry into the bloodstream), Distribution (movement to tissues), Metabolism (biotransformation, mainly hepatic), and Excretion (elimination, mainly renal).

2. What is first-pass metabolism and which route avoids it?

   First-pass metabolism is hepatic breakdown of an orally absorbed drug via the portal vein before reaching systemic circulation, reducing bioavailability. IV, sublingual, rectal, and inhalational routes largely bypass it.

3. Define bioavailability (F) and state its value for an intravenous drug.

   Bioavailability is the fraction of an administered dose reaching systemic circulation unchanged. For an IV drug, F = 1 (100%).

4. What is the elimination half-life (t1/2), and roughly how many half-lives are needed to reach steady state or eliminate a drug?

   The time required for plasma drug concentration to fall by 50%. About 4-5 half-lives are needed to reach steady state or to essentially eliminate a drug (~94-97%).

5. Which cytochrome P450 enzyme metabolizes the largest fraction of clinically used drugs, and where is it predominantly located?

   CYP3A4, located predominantly in the liver and intestinal wall.

6. What is the difference between Phase I and Phase II hepatic metabolism reactions?

   Phase I reactions (oxidation, reduction, hydrolysis; mainly CYP450) introduce/expose functional groups. Phase II reactions (conjugation such as glucuronidation, sulfation, acetylation) attach polar groups to increase water solubility for excretion.

7. How does the loading dose differ from the maintenance dose in calculation?

   Loading dose = (Vd x target concentration) / F; it rapidly achieves therapeutic level. Maintenance dose = (Clearance x target concentration x dosing interval) / F; it replaces eliminated drug to keep steady state.

8. Define volume of distribution (Vd) and what a large Vd indicates.

   Vd = amount of drug in body / plasma concentration. A large Vd indicates extensive distribution into tissues (e.g., lipophilic drugs) rather than remaining in plasma.

9. How does urine pH affect excretion of weak acids and weak bases (ion trapping)?

   Alkaline urine enhances excretion of weak acids (ionized, trapped) e.g., aspirin overdose treated with bicarbonate. Acidic urine enhances excretion of weak bases. Ionized drug is trapped in the tubule and excreted.

10. What is the difference between drug efficacy and drug potency?

    Efficacy is the maximal effect a drug can produce (Emax). Potency is the amount of drug needed to produce a given effect (related to EC50/ED50); a more potent drug needs a lower dose.

11. Define agonist, antagonist, and partial agonist.

    Agonist: binds and activates a receptor to produce a full response. Antagonist: binds but produces no response and blocks agonists. Partial agonist: binds and produces a submaximal response even at full occupancy.

12. What is the therapeutic index (TI), and does a high or low TI indicate a safer drug?

    TI = TD50/ED50 (or LD50/ED50). A high TI indicates a wide safety margin (safer); a low TI (e.g., warfarin, digoxin, lithium) requires careful monitoring.

13. Differentiate competitive from non-competitive antagonism in terms of dose-response curve effects.

    Competitive antagonists shift the agonist dose-response curve to the right (reduced potency) but Emax is unchanged and surmountable with more agonist. Non-competitive antagonists lower Emax (reduced efficacy) and cannot be overcome.

14. What is the ED50 on a quantal dose-response curve?

    The dose at which 50% of the population shows the specified therapeutic response.

15. Distinguish pharmacokinetic from pharmacodynamic drug interactions.

    Pharmacokinetic interactions alter a drug's absorption, distribution, metabolism, or excretion (changing its concentration). Pharmacodynamic interactions alter the drug's effect at the site of action (additive, synergistic, or antagonistic) without changing concentration.

16. What is a CYP enzyme inducer vs inhibitor, and how does each affect plasma levels of a co-administered substrate?

    An inducer (e.g., rifampin, carbamazepine, phenytoin) increases enzyme activity, lowering substrate levels and effect. An inhibitor (e.g., erythromycin, ketoconazole, grapefruit juice) decreases activity, raising substrate levels and toxicity risk.

17. What are the cholinergic (muscarinic) effects produced by parasympathetic stimulation relevant to dentistry?

    Increased salivation, lacrimation, sweating, bronchoconstriction, bradycardia, miosis, and increased GI motility (rest-and-digest, SLUDGE effects).

18. Which adrenergic receptor mediates vasoconstriction, and which mediates increased heart rate?

    Alpha-1 receptors mediate vasoconstriction; beta-1 receptors mediate increased heart rate and contractility (beta-2 mediates bronchodilation and vasodilation in skeletal muscle).

19. Why is epinephrine added to local anesthetics, and which receptor does it act on locally?

    Epinephrine causes local vasoconstriction via alpha-1 receptors, prolonging anesthetic duration, reducing systemic absorption/toxicity, and providing hemostasis.

See more Pharmacology and Pain/Anxiety Management flashcards →

Planning Pharmacology and Pain/Anxiety Management for National Board Dental Examination / Integrated National Board Dental Examination (INBDE)

Pharmacology and Pain/Anxiety Management (National Board Dental Examination / Integrated National Board Dental Examination (INBDE)) FAQ